Wolf Popper LLP Investigates the Proposed Acquisition of Asterias Biotherapeutics, Inc. by BioTime, Inc.

NEW YORK, Nov. 8, 2018 /PRNewswire/ -- Wolf Popper LLP is investigating claims on behalf of investors in Asterias Biotherapeutics, Inc. AST concerning the proposed acquisition of Asterias by BioTime, Inc.  According to Carl Stine, a partner at Wolf Popper LLP, "BioTime seems to be trying to use its 40% ownership and insider knowledge to force through a transaction that would provide Asterias shareholders with what appears to be a drastically unfair exchange ratio."    

Under the terms of the proposed acquisition, Asterias's shareholders will receive only $1.49 per share in BioTime common stock.  Price targets of every analyst who provides such targets are $12.00, $11.00, $6.00, and $5.50 per share.  Asterias shareholders seeking more information about the transaction or Wolf Popper's investigation can contact Mr. Stine at (212) 759-4600 or cstine@wolfpopper.com.

Wolf Popper has extensive experience representing investors in mergers and acquisition lawsuits.  Ten Wolf Popper attorneys were named Super Lawyers or Rising Stars in the 2018 Super Lawyers New York City Metro Edition, including Wolf Popper partner Carl Stine, who was included in the Super Lawyers Top 100 List for the New York City Metro area.  View Wolf Popper attorney biographies at www.wolfpopper.com.

Attorney Advertising: Prior Results Do Not Guarantee A Similar Outcome.

Wolf Popper LLP

845 Third Avenue

New York, New York 10022

Telephone: 212-759-4600

Toll Free Tel: 877-370-7703

Toll Free Fax: 877-370-7704

Email: cstine@wolfpopper.com

View original content:http://www.prnewswire.com/news-releases/wolf-popper-llp-investigates-the-proposed-acquisition-of-asterias-biotherapeutics-inc-by-biotime-inc-300746787.html

SOURCE Wolf Popper LLP